αMT

Closure of psx:substance/amt/section/pharmacology.full@1: 32 upstream, 33 downstream.

psx:substance/amt/section/pharmacology.full@1
├─ informed_by  claim/b7e15848-0317-433a-a36d-35f77fc508e0  Claim in pharmacology — supported
├─ informed_by  claim/418427c4-f4cd-438d-923b-f1ee7eb2468a  Claim in pharmacology — supported
├─ informed_by  claim/bd0247ba-baad-4846-9e6e-0fc37a5f92ac  Claim in pharmacology — supported
├─ informed_by  claim/ea701648-c981-4e78-a22a-937c592618cc  Claim in pharmacology — supported
├─ informed_by  claim/c63e4711-7a26-4467-8cc7-15e13361a3b6  Claim in pharmacology — supported
├─ informed_by  claim/6f730c06-7aab-4b75-8c4a-2ff1a68f8a3b  Claim in pharmacology — inconclusive  working
├─ informed_by  claim/323a5799-a2f4-49c5-a891-e269509455d7  Claim in pharmacology — supported
├─ informed_by  claim/3e988bd4-e133-45d4-9982-958b8c84e390  Claim in pharmacology — supported
  ├─ used  src/doi:10.1016/j.toxlet.2017.03.007  In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks.
  ├─ used  src/pmid:3091132  The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.
  ├─ used  src/doi:10.1016/j.neures.2025.04.006  A systematic study of changes in monoamine neurotransmitters in the rat brain following acute administration of alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT).
  ├─ used  src/doi:10.1021/acschemneuro.5c00468  Dual Modulation of 5-HT2A Receptors and SERT by α-Ethyltryptamine and Its Optical Isomers.
  ├─ used  src/doi:10.1097/FBP.0000000000000841
  ├─ used  src/doi:10.1007/s00204-015-1513-x  The hallucinogenic world of tryptamines: an updated review.
  ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
  ├─ used  src/doi:10.3390/metabo13010092  Alpha-methyltryptamine (alpha-MT) Metabolite Profiling in Human Hepatocyte Incubations and Postmortem Urine and Blood
      ├─ used  src/url:20cb97e3473fcc7c  Alpha-methyltryptamine (Indopan) - NCATS Inxight Drugs
      ├─ used  src/pmid:12678045  Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
      ├─ used  src/doi:10.1016/j.expneurol.2021.113638  New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review.
      ├─ used  src/doi:10.1021/acschemneuro.2c00170  Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
      ├─ used  src/doi:10.1016/j.bbr.2018.07.020  5-Methoxy-alpha-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex.
      ├─ used  src/url:3c1fc77ba0385127  AMT Drug Information - DrugWise
      ├─ used  src/doi:10.2174/1570159X13666141210222409
      ├─ used  src/pmid:16105268  Fatality due to acute alpha-methyltryptamine intoxication.
      ├─ used  src/pmid:15455477  Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
      ├─ used  src/url:c29bc5afd23f85d7  Legal Status of Alpha-methyltryptamine - Multiple Jurisdictions
      ├─ used  src/url:3ad72d5c592d8337  Release.org.uk - AMT Drug Information
      ├─ used  src/doi:10.1007/s00213-021-05876-x  Serotonin toxicity of serotonergic psychedelics
      ├─ used  src/doi:10.1007/s00414-024-03236-w  Alpha-methyltryptamine and 5-(2-methylaminopropyl)-benzofuran (5-MAPB) fatal co-intoxication: case report and review of literature
      ├─ used  src/doi:10.3109/15563650.2014.885983  Patterns of presentation and clinical toxicity after reported use of alpha methyltryptamine in the United Kingdom. A report from the UK National Poisons Information Service.
      ├─ derived_from  gen/fa205cf9-0ea6-4773-8b45-a7f571ae0dd9  Generation — pipeline-v5
      └─ generated_by  pub/793ed85a-cf09-4c5b-a475-4376fad1f033  Publication — backfill
    ├─ used  version/1  Revision 1
    ├─ used  claim/0914056a-a5bc-43ed-94cb-26f65f6994da  Claim in summary — partially_supported
    ├─ used  claim/8c774afa-5b04-4340-b20a-210c04c1a045  Claim in safety — partially_supported
    ├─ used  claim/5e3c02ae-da98-49f7-9206-ae67027acf63  Claim in safety — supported
    ├─ used  claim/6b63dbcb-9efc-4326-bb37-263d3f309ec5  Claim in pharmacokinetic-detail — partially_supported
    ├─ used  claim/a04c56e4-559a-4884-a789-4da63c2f2fdb  Claim in summary — partially_supported
    ├─ used  claim/3a7b820a-cc89-4ca2-9b00-5da84ae33326  Claim in neuroscience — supported
    ├─ used  claim/f908de86-eec0-4ee2-9be6-717e35da37a5  Claim in chemistry — partially_supported
    ├─ used  claim/fe144654-607b-4337-a5de-29d4d7255c5c  Claim in receptor-pharmacology — partially_supported
    ├─ used  claim/93850a31-26ea-4224-bb79-6f333eff9c03  Claim in comparative-pharmacology — partially_supported
    ├─ used  claim/66a242f9-a9cc-4e18-b920-43b0e5967191  Claim in neuroscience — supported
    ├─ used  claim/7fa5ba46-98f6-42fc-9c5d-1e64280dad5a  Claim in summary — supported
    ├─ used  claim/f97570f5-ca7f-4341-8c43-28827252248c  Claim in safety — inconclusive  working
    ├─ used  claim/a7749afd-fff3-4fb4-a28b-d2fbd3fbe602  Claim in neuroscience — inconclusive  working
    ├─ used  claim/6ce627df-2f99-46ec-b055-f65fc6f7d4fe  Claim in neuroscience — supported
    ├─ used  claim/f2bf8b6a-1a74-4b53-94ff-663bf2cb019e  Claim in history — supported
    ├─ used  claim/71340da0-c9b1-4bae-9944-fee7dbf42f21  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/223a26f6-954e-4f37-87c0-057c5997b57e  Claim in comparative-pharmacology — supported
    ├─ used  claim/2d7d5a8e-f271-40c8-8805-8ade7aa8d113  Claim in pharmacokinetic-detail — supported
      ├─ derived_from  issue/notice@76ddbaed5b37  Issued notice
      ├─ derived_from  issue/info_card@46bc1bb853c0  Issued info_card
      ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
      ├─ derived_from  issue/notice@a5727d1128c1  Issued notice
      ├─ derived_from  issue/info_card@edd9e6b4fbff  Issued info_card
      ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/safety.full@1
      ├─ informed_by  section/pharmacokinetic-detail.full@1
      ├─ informed_by  section/neuroscience.full@1
      ├─ informed_by  section/chemistry.full@1
      ├─ informed_by  section/receptor-pharmacology.full@1
      ├─ informed_by  section/comparative-pharmacology.full@1
      └─ informed_by  section/history.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage